{"entity":{"id":"nct06486142","kind":"trial","name":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","aka":[],"tldr":"A phase 3 trial of Afatinib, Dacomitinib and Osimertinib in Non-small-cell lung cancer, run by Region Skane, now recruiting.","summary":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study is a phase 3 interventional study registered as NCT06486142 by Region Skane, with 200 participants planned, started 2022-09-21 and due to reach its primary completion in 2028-09. Interventions recorded: Afatinib/Dacomitinib, Osimertinib. Conditions recorded: Non-Small Cell Lung Cancer.\n\nLinked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06486142","url":"https://clinicaltrials.gov/study/NCT06486142"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["afatinib","dacomitinib","osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06486142","phase":"3","setting":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","sponsor":"Region Skane","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06486142/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/"},{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}]}}